OTC Version Of Santarus' Zegerid Approved

The Food and Drug Administration approved an over the counter version of Santarus Inc.'s (Nasdaq: SNTS) heartburn treatment Zegerid made by Merck & Co. Inc. (NYSE: MRK). Shares of Santarus climbed 62 cents to $4.91 while Merck stock eased 28 cents to $36.60.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.